INTRODUCTION

The self-expanding biliary metal stent has been shown to have a longer patency compared to the polyethylene stent and is therefore a good alternative in patients with malignant biliary stricture. This is especially useful in patients unsuitable for open surgery. Several randomised trials showed no significant difference in long-term survival between patients treated with surgical bypass and stenting. Endoscopic stenting results in lower procedural-related mortality, shorter hospital stay and a lower major complication rate, whereas surgical bypass is associated with fewer late complications such as stent clogging, which necessitates re-admission. This retrospective study evaluates our experience of percutaneous Wallstent insertion after a failed endoscopic (ERCP) stent insertion.

PATIENTS AND METHODS

Between February 1996 and January 1999, 283 ERCP studies were performed. Nineteen patients (6.7%) with advanced malignant obstructive biliary disease underwent percutaneous metal stent insertion following a failed endoscopic approach due to their advanced disease. Seventeen (89.5%) were successful. Eight patients had pancreatic tumour, five had liver metastases from either lung or colorectal tumour and four had cholangiocarcinoma. Curative operation was considered unsuitable in all the cases because of co-morbidity, operative risk factors and the advanced disease stage. The level of activity of daily living, the decrease in bilirubin, symptoms improvement (reduced pruritus and improved appetite), and the hospital re-admission rate for stent-related complications were assessed. The complication and mortality rates were then compared to the published data.

The Wallstent prosthesis was placed percutaneously by a radiologist. Thirteen patients were given intravenous antibiotic and all were given lignocaine, midazolam and pethidine for the procedure. The Wallstents used were either 10mm x 9cm or 10mm x 7cm Schneider "place hit" Wallstent. These are self-expanding stents loaded on a 9F delivery system and when released would continue to expand up to 10mm after deployment (Figure 1). Some patients also had dilatation of the stricture with angioplasty probe prior to stent insertion.

RESULTS

Outcome

The majority of the patients treated were male and 70 years or older (Figure 2). Sixteen patients (94%) had a fall in bilirubin concentration of more than 20% following the procedure (Figures 3 and 4). One patient with a pancreatic tumour had an insignificant drop in bilirubin of 7%. Only three patients did not leave the hospital and died one to two months later. All three, however, had significant reductions in pruritus and bilirubin level and improvement in appetite. Fourteen patients (82%) were discharged following Wallstent insertion and all were able to function independently in the community with palliative care support.

Complications

Seven patients (41%) required re-admission for various reasons following stent insertion. However, only two (12%)
were re-admitted for stent-related problems (re-occlusion and cholangitis). One patient, unfortunately, was re-admitted on eight occasions over three years for recurring cholangitis and re-occlusion despite taking longterm prophylactic antibiotics. These episodes were successfully treated with dredging of the stent and intravenous antibiotics. The five remaining patients were re-admitted for reasons which include gastrointestinal bleeding, ascitic drainage, pulmonary embolism, bone pain, chemotherapy and prostatic biopsy.

Mortality

There were no procedure-related deaths and the overall thirty-day mortality rate was 6% (Table 1). All the patients died of primary disease. The median survival was longest in patients with cholangiocarcinoma, followed by pancreatic tumour and metastatic disease (42 weeks, 16 weeks and seven weeks respectively) (Figure 5). The overall median survival in our study was 3.5 months (Table 2).

![Figure 2 Gender vs age group](image)

![Figure 3 Serum bilirubin pre and post stenting](image)

![Figure 4 Percentage fall in serum bilirubin](image)

![Figure 5 Survival vs diagnosis](image)

**DISCUSSION**

Percutaneous self-expanding Wallstents provide good palliation for patients with inoperable malignant obstructive jaundice. Davids et al found that the median patency was significantly prolonged in patients with metal stents compared with polyethylene stents (273 days versus 176 days). The main reason for metal stent occlusion is tumour ingrowth through the meshes, or tumour overgrowth at the end of the stents. Only two patients in our series were re-admitted with cholangitis and occlusion (12%) and none of these had tumour ingrowth. This may be explained by the shorter survival among our patients due to the advanced stage of their disease.

Up to 40% of patients in one series had sepsis following stent insertion despite prophylactic antibiotics. Our results compared favourably as no patients in our study had early complications following the procedure. The European Wallstent Study Group reported longterm complications manifested by late cholangitis in 18% of cases and occlusion by biliary sludge in 5%. Our results again compared favourably as only two patients (12%) had to be re-admitted for stent occlusion. One patient in our series with cholangiocarcinoma had to be re-admitted on several occasions over three years for recurring cholangitis and died of primary disease. The median survival was longest in patients with cholangiocarcinoma, followed by pancreatic tumour and metastatic disease (42 weeks, 16 weeks and seven weeks respectively) (Figure 5). The overall median survival in our study was 3.5 months (Table 2).
occasions over a three-year period with recurrent cholangitis and occlusions due to biliary sludge and debris despite taking longterm prophylactic antibiotics. These were treated successfully with balloon trawling of the stent and intravenous antibiotics.

Although high bilirubin level has been described as an unfavourable factor affecting stent patency", neither of our two patients re-admitted for occlusion of their metal stent had a particularly high bilirubin level prior to stent insertion (150, 292). Drainage of bile was satisfactory in all our patients following the procedure. The bilirubin level was reduced by more than 20% in 94% of cases. This is highly significant as it improves the symptoms of pruritus, increases appetite and hence improves general wellbeing.

Fourteen patients (82%) were discharged following a metal stent insertion. All these patients achieved a reasonable level of independent activity of daily living with the support of a palliative care team. Three of our patients (18%) did not leave the hospital after metal stent insertion as they were too frail. Nonetheless, they all felt better and had improved appetite and reduced pruritus. This is important as it causes less distress for patients and their families. The hospital re-admission rate for stent-related problems was considered low (12%) with patients spending more time at home.

The overall survival in our series was 3.5 months which is short compared to others (Table 2) and reflects the more advanced disease stage in our patient cohort. Our data compare favourably in terms of thirty-day procedure-related mortality and complications (Table 1). Only one patient in our series died within thirty days post-procedure of primary disease and general deterioration.

In conclusion, our study confirmed that percutaneous Wallstent insertion offers good palliation, improves general wellbeing and enhances the level of independent activity of daily living in patients with malignant biliary obstruction. Percutaneous approach is a good alternative after a failed endoscopic approach in the very frail patients, and this is often preferable to an open operation. This procedure can safely be performed in a district general hospital.

Acknowledgement
We are indebted to Dr N Grunshaw for providing the technical support.

REFERENCES


8 O’Brien S, Hatfield ARW, Craig PI, Williams SP A three-year follow-up of self-expanding metal stents in the endoscopic palliation of longterm survivals with malignant biliary obstruction Gut 1995;36:618-621


